Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2002-11-29
2010-02-09
Chin, Christopher L (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S811000
Reexamination Certificate
active
07659075
ABSTRACT:
Method for early differential diagnosis and detection, for prognosis and assessment of the severity and for therapy-accompanying assessment of the course of sepsis and sepsis-like systemic infections, in which, preferably with additional determination of at least one further parameter suitable for sepsis diagnosis, the amount of soluble cytokeratin fragments, in particular of CYFRA 21-1, TPS, TPA and/or sCY1F, in a biological fluid of a patient in whom a sepsis is present or a sepsis is suspected is determined and conclusions with regard to the presence, the expected course, the severity and/or the success of initiated measures for the therapy of the sepsis are drawn from the determined amount of soluble cytokeratin fragments.
REFERENCES:
patent: 5639617 (1997-06-01), Bohuon
patent: 5660994 (1997-08-01), Bruder-Heid et al.
patent: 6207380 (2001-03-01), Billing-Medel et al.
patent: 7132246 (2006-11-01), Bergmann et al.
patent: 7157081 (2007-01-01), Bergmann et al.
patent: 7405049 (2008-07-01), Bergmann et al.
patent: 7413850 (2008-08-01), Bergmann et al.
patent: 2002/0103141 (2002-08-01), McKearn et al.
patent: 2004/0002125 (2004-01-01), Gombrich et al.
patent: 2005/0059104 (2005-03-01), Bergmann et al.
patent: 2005/0064506 (2005-03-01), Bergmann et al.
patent: 2005/0239150 (2005-10-01), Bergmann et al.
patent: 2006/0029990 (2006-02-01), Bergmann et al.
patent: 2006/0035221 (2006-02-01), Bergmann et al.
patent: 2006/0115869 (2006-06-01), Bergmann et al.
patent: 2006/0234295 (2006-10-01), Bergmann et al.
patent: 198 47 690 (2000-04-01), None
patent: 101 19 804 (2002-10-01), None
patent: 101 30 985 (2003-01-01), None
patent: 101 31 922 (2003-01-01), None
patent: 1 318 405 (2004-11-01), None
patent: WO 00/22439 (2000-04-01), None
patent: WO 02/085937 (2002-10-01), None
patent: WO 03/002600 (2003-01-01), None
patent: WO 03/005035 (2003-01-01), None
Vogl et al. Clinical Biochemistry vol. 28 (1995), pp. 291-295.
Mayeux et al. “Biomarkers: Potential uses and Limitations”; NeuroRx (2004); vol. 1, pp. 182-188.
Dobashi et al. “Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia” Eur Respir J 1999; 14: 574-578.
Tempfer et al. “CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases” Br J Cancer. Oct. 1998;78(8):1108-12; abstract only.
Bast et al. “Translational Crossroads for Biomarkers” Clin Cancer Res 2005; 11(17), 6103-6108.
LaBaer et al. “So, You Want to Look for Biomarkers” Journal of Proteome Research 2005; 4, 1053-1059.
Baker “In Biomarkers We Trust?” Nature Biotechnology 2005; 23(3), 297-304.
Harlow, E. and Lane, D., Antibodies: A Laboratory Manual (1988) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 23-25.
Williams, M.D. et al. “Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care” Critical Care 2004, 8:R291-R298 (DOI 10.1186/cc2893.
Advisory Action dated Oct. 14, 2008 in co-pending U.S. Appl. No. 10/496,096; RCE filed Nov. 24, 2008.
Office Action dated Nov. 13, 2008 in co-pending U.S. Appl. No. 10/496,250.
Final Rejection dated Oct. 14, 2008 in co-pending U.S. Appl. No. 10/497,679.
Final Rejection dated Oct. 31, 2008 in co-pending U.S. Appl. No. 10/516,618.
Office Action dated Jul. 9, 2008 in co-pending U.S. Appl. No. 10/496,173.
Aird, “The Hematologic System as a Marker of Organ Dysfunction in Sepsis,”Mayo Clin, Proc., 78:869-881, 2003.
Assicot, et al., “High Serum Procalcitonin Concentrations in Patients with Sepsis and Infection,”Lancet, 341(8844):515-518, 1993.
Beishuizen et al, “Endogenous Mediators in Sepsis and Septic Shock,”Advances Clin. Chem., 33:55-131, 1999.
Carrigan et al., “Toward Resolving the Challenges of Sepsis Diagnosis,”Clin. Chem., 50(8):1301-1314, 2004.
Ebert et al., “CYFRA 21-1—Clinical Applications and Analytical Requirements,”Scand J. Clin. Lab. Invest., 55 Suppl. 221:72-80, 1995.
Einarsson and Rydlander, “Tissue Polypeptide Specific Antigen (TPS) Detects a Specific Epitope Structure on Human Cytokeratin,”Anticancer Research, 17:3121-3124, 1997.
Gabay and Kushner, “Acute-Phase Proteins and Other Systemic Responses to Inflammation,”New Engl. J. Med., 340(6):448-454, 1999.
Hotchkiss and Karl, “The Pathophysiology and Treatment of Sepsis,”N. Engl. J. Med., 348(2):138-150, 2003.
Karzai, et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infections,”Infection, 25:3-8, 1997.
Kim et al., “Different Cutoff Values of Cyfra 21-1 for Cavitary and Noncavitary Lung Cancers,”Lung Cancer, 30:187-192, 2000.
Marshall et al., “Measures, Markers, and Mediators: Toward a Staging System for Clinical Sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, Oct. 25-26, 2000,”Crit. Care Med., 31(5):1560-1567, 2003 (Abstract only).
Nisman et al., “Evaluation of Tissue Polypeptide Specific Antigen, CYFRA 21-1, and Carcinoembryonic Antigen in Nonsmall Cell Lung Carcinoma,”Cancer, 82:1850-1859, 1998.
Oberholzer et al., “Sepsis Syndromes: Understanding the Role of Innate and Acquired Immunity,”Shock, 16(2):83-96, 2001 (Abstract only).
Oczenski et al., “Procalcitonin: A New Parameter for the Diagnosis of Bacterial Infection in the Peri-Operative Period,”Eur. J. Anaesthesiol., 15:202-209, 1998.
Redl et al., “Procalcitonin Release Patterns in a Baboon Model of Trauma and Sepsis: Relationship to Cytokines and Neopterin,”Crit. Care Med., 28(11):3659-3663, 2000.
Redl and Schlag, “Non-Human Primate Models of Sepsis,”Sepsis, 2:243-253, 1998.
Reinhart et al., “Sepsis Und Spetischer Schock,”Intensivmedizin, 756-760, 2001.
Rylander et al., “Molecular Characterization of a Tissue-Polypeptide-Specific-Antigen Epitope and its Relationship to Human Cytokeratin 18,”Eur. J. Biochem., 241:309-314, 1996.
Sarwar et al., “CYFRA 21-1 as a Tumor Marker Used in Measuring the Serum Fragment of Cytokeratin Subunit 19 by Immunoradiometric Assay,”Annals of Nucl. Med., 8(4), 301-306, 1994.
Stearns et al., “Circulating Tumor Markers in Breast Cancer: Accepted Utilities and Novel Prospects,”Breast Cancer Research Treatment, 52:239-259, 1998.
Stieber, “34.10 CYFRA 21-1 (Cytokeratin-19-Fragmente),”Thomas Labor Diagnose, 987-992, 2000.
Streicher et al., “Anticytokeratins Are a Potential Source of False-Positive Indirect Immunofluorescence Assays for C-ANCA,”J. Clin.Lab. Analys., 12:54-59, 1998.
Sutterlin et al., “Clinical Value of CYFRA 8/18 and TPS in the Diagnosis and Follow Up of Invasive Breast Cancer,”Anticancer Research, 17:2963-2966, 1997.
Trevisani et al., “Cytokeratin Tumor Marker Levels in Bronchial Washing in the Diagnosis of Lung Cancer,”Chest, 109:104-108, 1996.
Wolff et al., “Tissue Polypeptide Specific Antigen Serum Concentrations in Patients with Newly Diagnosed Prostatic Diseases,”Anticancer Research, 20:5003-5006, 2000.
Yao et al., “Clinicopathologic Correlation of Serum Tissue Polypeptide Specific Antigen in Hepatocellular Carcinoma,”Oncology, 61:64-70, 2001.
International Search Report for EPO Application No. 01128851.1, mailed Jun. 4, 2002.
International Search Report for PCT Application No. PCT/EP 02/13526, mailed Nov. 29, 2002.
B.R.A.H.M.S Aktiengesellschaft
Chin Christopher L
Foster Christine
Heslin Rothenberg Farley & & Mesiti P.C.
LandOfFree
Method for the diagnosis of sepsis with determination of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the diagnosis of sepsis with determination of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the diagnosis of sepsis with determination of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199031